Pierre Fabre

Institut Curie, Pierre Fabre Partner on immuno-oncology

Friday, October 20, 2017

Institut Curie and the IRPF (Institut de Recherche Pierre Fabre) will collaborate on new therapeutic strategies to advance cancer treatment for patients. The objective of this novel partnership is to dissect the biology of novel therapeutically tractable targets and evaluate the impact of innovative pharmacological approaches leveraging the Institut Curie’s biological models.

[Read More]

Pierre Fabre, H-Immune partner to develop cancer immunotherapies

Tuesday, March 21, 2017

Pierre Fabre, a privately held pharmaceutical company in France, and H-Immune, an emerging biotechnology company focused on developing first in class immunotherapies for treatment of various cancers, have entered into a strategic research partnership which will utilize H-Immune’s unique technology platform to generate lead candidates of fully human antibodies to serve as the initial step in a program to develop immuno-oncology therapeutics.

[Read More]

PIQUR Therapeutics, Pierre Fabre partner in dermato-oncology

Thursday, January 12, 2017

PIQUR Therapeutics, a Swiss clinical-stage pharmaceutical company, and Pierre Fabre, the second largest private French pharmaceutical group, have signed a collaboration agreement for the development of PIQUR’s lead compound PQR309 in dermato-oncology. The exclusive deal will see PIQUR and Pierre Fabre’s R&D teams work together on the evaluation and development of dermatological formulations of PI3K/mTOR inhibitors across multiple therapeutic indications. 

[Read More]

Array, Pierre Fabre collaborate on oncology

Monday, November 16, 2015

Array BioPharma and Pierre Fabre are collaborating to globally develop and commercialize Array’s late-stage novel oncology products binimetinib and encorafenib. Binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, currently are advancing in three global phase III trials for melanoma and ovarian cancer. Top-line results from NEMO, a phase III study of binimetinib in patients with NRAS-mutant melanoma, are anticipated before the end of 2015.

[Read More]

Redx Pharma, Pierre Fabre Laboratories to collaborate on cancer research

Friday, March 7, 2014

Redx, a provider of translational research capacity and experience in cancer stem cells, tumor immunology and anti-microbial resistance, and Pierre Fabre Research Institute (IRPF) have formed an agreement for cancer research. The exclusive deal will see Redx and IRPF work together on the evaluation and development of a small molecule program for an undisclosed oncology target. Following the first stage of the collaboration, IRPF will have the option to enter into exclusive negotiations to license global rights for the program in selected cancer indications.

[Read More]